Putative binding modes of clinical PROTACS
The PROTAC company Arvinas has created history by nominating two of the PROTACS to the clinic, viz. ARV-110 and ARV-471 in 2019. Recently the structures of the clinical candidates were shared. Many congratulations to the whole team on these milestones.
We at thinkMolecular got curious about the binding modes and here we show the potential modes of binding of the two clinical candidates.
ARV-471 - Estrogen receptor degrader
ARV-110 – Estrogen receptor degrader
Putative binding mode of the PROTAC ARV-110 on the complex of AR and CRBN[/caption]
If you want to find out more about the methods employed and our capabilities, do reach out at info@thinkmolecular.in. It would be fun to compare with the PDB some day (AFAWK not released yet).
This was generated using ICM of MolSoft LLC,
#PROTAC #drugdiscovery